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Epigenetic and genetic alterations have long been thought of as two separate mechanisms participating in
carcinogenesis. A recent outcome of whole exome sequencing of thousands of human cancers has been
the unexpected discovery of many inactivating mutations in genes that control the epigenome. These muta-
tions have the potential to disrupt DNA methylation patterns, histone modifications, and nucleosome posi-
tioning and hence, gene expression. Genetic alteration of the epigenome therefore contributes to cancer
just as epigenetic process can cause point mutations and disable DNA repair functions. This crosstalk
between the genome and the epigenome offers new possibilities for therapy.Cancer has traditionally been viewed as a set of diseases that
are driven by the accumulation of genetic mutations that have
been considered the major causes of neoplasia (Hanahan and
Weinberg, 2011). However, this paradigm has now been
expanded to incorporate the disruption of epigenetic regulatory
mechanisms that are prevalent in cancer (Baylin and Jones,
2011; Sandoval and Esteller, 2012).
Both genetic and epigenetic views ultimately involve abnormal
gene expression. The expression state of a particular gene is
determined by the packaging of its DNA regulatory regions at
promoters and/or enhancers and insulators in chromatin and
by the presence of TFs and chromatin modifying enzymes. The
genetic path to cancer is relatively straightforward: mutation of
tumor suppressors and/or oncogenes causes either loss or
gain of function and abnormal expression. The epigenetic
pathway to cancer is not as simple and is determined by chro-
matin structure including DNA methylation, histone variants
and modifications, nucleosome remodeling as well as small
non-coding regulatory RNAs (Sharma et al., 2010). During tumor
initiation and progression, the epigenome goes through multiple
alterations, including a genome-wide loss of DNA methylation
(hypomethylation), frequent increases in promoter methylation
of CpG islands, changes in nucleosome occupancy, and modifi-
cation profiles.
More recently, intriguing evidence has emerged that genetic
and epigenetic mechanisms are not separate events in cancer;
they intertwine and take advantage of each other during tumor-
igenesis. Alterations in epigenetic mechanisms can lead to
genetic mutations, and genetic mutations in epigenetic regula-
tors lead to an altered epigenome. In this review, we will discuss
the collusion between epigenetics and genetics in cancer.
How Epigenetics Affect Genetics
Epigenetic mechanisms help establish cellular identities, and
failure of the proper preservation of epigenetic marks can
result in inappropriate activation or inhibition of various cellular
signaling pathways leading to cancer. It is now generally
accepted that human cancer cells harbor global epigenetic
abnormalities and that epigenetic alterations may be the key toinitiating tumorigenesis (Baylin and Jones, 2011; Sandoval and
Esteller, 2012; Sharma et al., 2010). The cancer epigenome is
characterized by substantial changes in various epigenetic
regulatory layers; herein, we introduce some important exam-
ples of epigenetic disruptions that cause mutation of key genes
and/or alteration of signaling pathways in cancer development.
Epigenetic Silencing Causes the Loss of Function
of Genes and Predisposes to Genetic Mutation
Promoter hypermethylation of classic tumor suppressor genes is
commonly observed in cancers, a phenomenon that has been
implicated with driving tumorigenesis (Baylin and Jones, 2011).
Genes controlling the cell cycle and DNA repair, such as RB,
BRCA1/2, and PTEN, have all been reported to be hypermethy-
lated or mutated/deleted in cancer (Hatziapostolou and Iliopou-
los, 2011). There are also several genes that are seldommutated
but are silenced in cancer; promoter hypermethylation is the
predominant mechanism for the loss of their functions (Baylin
and Jones, 2011). O6-methylguanine-DNA methyltransferase
(MGMT), which encodes a DNA repair gene, Cyclin-dependent
kinase inhibitor 2B (CDKN2B), which encodes a cell cycle regu-
lator p15, and RASSF1A, which encodes a protein that binds to
the RAS oncogene all belong to this category, and they have
been implicated with protective roles against tumorigenesis.
Several DNA repair genes are known to be subject to promoter
methylation. MGMT removes carcinogen-induced O6-methyl-
guanine adducts from DNA, which result in G to A transition
mutations. Cancers with hypermethylated MGMT are suscep-
tible to genetic mutation in critical genes such as p53 or KRAS
(Baylin and Jones, 2011; Esteller, 2007). The mismatch-repair
gene MLH1 plays an important role in genomic stability, and
the loss of function of this gene by promoter hypermethylation
causes microsatellite instability, which is a key factor in several
cancers, including colorectal and endometrial cancers (Krivtsov
and Armstrong, 2007). The MLH1 promoter is already hyperme-
thylated in normal colonic epithelium of some colorectal cancer
patients, suggesting this epigenetic change is an early event of
tumorigenesis and precedes downstream genetic mutation
(Hitchins et al., 2011). Notably, SNVs of MLH1 50UTR are corre-
lated with the hypermethylation of its promoter, highlightingCancer Cell 22, July 10, 2012 ª2012 Elsevier Inc. 9
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cancer (Hitchins et al., 2011).
Epigenetic Silencing Facilitates the Selection
of Mutations in Key Signaling Pathways
Direct evidence for a close epigenetic-genetic cooperation is
apparent in the colon cancer cell line HCT116 in which one allele
ofMLH1 and CDKN2A is genetically mutated, whereas the other
allele is silenced by DNA methylation (Baylin and Ohm, 2006).
The lack of functional expression of MLH1 and CDKN2A causes
defects in DNA mismatch repair and cell cycle regulation.
Another example of epigenetic-genetic cooperation is in the
WNT signaling pathway (Schepers and Clevers, 2012). In normal
cells, secreted frizzled-related proteins (SFRPs) antagonizeWNT
signaling. Epigenetic silencing of SFRPs induces abnormal acti-
vation of this signaling pathway, further promoting the expres-
sion of several genes whose products are responsible for cell
proliferation. As a result of survival and proliferative advantages,
these cells accumulate genetic mutations in other components
of the WNT signaling pathway. There are also several examples
where epigenetic silencing allows abnormal proliferation path-
ways and increases the likelihood for mutation in genetic gate
keepers and increases cancer risk (Baylin and Jones, 2011).
More recent results from The Cancer Genome Atlas project
provide an integrative view of ovarian carcinoma based on inte-
grated genomic analyses (Network, 2011). The mutation spec-
trum is unexpectedly simple, showing the predominance of
p53 mutations and other low frequency mutations in nine genes
including BRCA1, BRCA2, and RB. On the other hand, promoter
hypermethylation is observed in 168 genes, and those genes are
epigenetically silenced and correlated with reduced expression.
It is noteworthy that clustering of variable DNA methylation
across tumors can identify subtypes. Indeed, the CpG island
methylator phenotype (CIMP) is reported in colorectal cancer
and glioblastoma, and this subgroup shows distinctive charac-
ters such as genetic and clinical features (Hinoue et al., 2012;
Noushmehr et al., 2010). A CIMP-high subgroup is strongly asso-
ciated with MLH1 DNA hypermethylation and BRAF mutation,
while a CIPM-low subgroup is related to KRASmutation (Hinoue
et al., 2012).
Role of 5-methylcytosine in Generating
Disease-Causing Mutations
Themethylation of cytosine residues in the germline has led to an
approximately 75% decrease in the frequency of CpG methyl
acceptor sites. This is thought to be due to the spontaneous
hydrolytic deamination of 5-methylcytosine (5mC) to thymine
rather than uracil, which is formed by deamination of cytosine.
The resulting T:G mismatch is more difficult to repair, and about
a third of all disease causing familial mutations and single nucle-
otide polymorphisms or variants (SNPs or SNVs) occur at meth-
ylated CpG sites. What is often overlooked is that the presence
of 5mC in the gene bodies and coding regions of genes such
as p53 is responsible for generating inactivating C to T transition
mutations, causing hotspots in somatic cells (Rideout et al.,
1990). For example, as many as 50% of p53 point mutations in
colon cancer occur at such sites, clearly demonstrating that an
epigenetic mark (5mC) directly causes somatic mutations.
More interestingly, a somatic DNMT3A hotspot mutation in
acute myeloid leukemia (AML) is caused by C to T transitions
at a CpG site, possibly due to the methylation of its own exon10 Cancer Cell 22, July 10, 2012 ª2012 Elsevier Inc.by the enzyme (epigenetic alteration) and the subsequent deam-
ination of 5mC (genetic mutation) (Ley et al., 2010) (Figure 1). The
effect of the point mutation is not yet fully understood since
methylation changes are not observed in the tumor. It is possible
that this mutation alters DNMT3A function and/or activity and
may further disrupt whole epigenetic regulation mechanism
(Figure 1).
Role of MicroRNA in Tumorigenesis
MicroRNAs (miRNAs) are a class of small noncoding RNAs
that play key roles in epigenetic regulation by controlling the
translation and/or stability of mRNAs. There are over 1,000
human miRNAs and, interestingly, these miRNAs frequently
target regions related to cancer development (Ryan et al.,
2010). They have been classified as oncogenic, tumor-suppres-
sive, or context-dependent miRNAs (Kasinski and Slack, 2011).
Indeed, oncogenic miRNAs such as miR-155 or miR-21 are
frequently overexpressed, and tumor suppressive miRNAs
such as miR-146 or miR-1516 are deleted in cancers (Kasinski
and Slack, 2011). Mutation in the miRNA can disrupt its recogni-
tion of binding targets and further result in oncogene activation
and/or tumor suppressor repression. Additionally miRNAs
including miR-101 and miR-29 target epigenetic modifiers
such as EZH2 (Friedman et al., 2009; Varambally et al., 2008)
and DNMT3A/B (Fabbri et al., 2007), respectively. This can result
in further widespread epigenetic alterations (Fabbri and Calin,
2010; Kasinski and Slack, 2011) and might lead to the methyla-
tion of promoters of other miRNAs that target oncogenes.
miR-127, which targets BCL6, is abnormally methylated and
silenced in cancer (Saito et al., 2006), highlighting the reciprocal
regulation of miRNAs, epigenetic modifiers, and genetic defects
in cancer.
Given the importance of epigenetic silencing in the develop-
ment of cancer, distinguishing ‘‘drivers’’ and ‘‘passengers’’ is
becoming an important priority for the field. Driver genes must
be essential for cancer causation, whereas passenger genes
are not necessary (Kelly et al., 2010). With the improvement of
technology, it may eventually be possible to specifically distin-
guish epigenetic disruptions of the driver genes (De Carvalho
et al., 2012; Kalari and Pfeifer, 2010). Current evidence shows
that epigenetic disruptionplays akey role at every stageof tumor-
igenesis and has a significant impact on the underlying mecha-
nisms of tumorigenesis and development of cancer therapy.
How Genetics Affect Epigenetics
While epigenetics and genetics can cooperate in cancer initia-
tion and progression, the interconnectedness between of these
two processes is becoming increasingly apparent with the real-
ization that several epigenetic modifiers are mutated in human
cancers (Kasinski and Slack, 2011; Rodrı´guez-Paredes and
Esteller, 2011; Schuettengruber et al., 2011;Wilson and Roberts,
2011). Some examples of genetic mutations of epigenetic
modifiers are shown in Table 1 and Figure 2. The mutation of
epigenetic modifiers presumably leads to profound epigenetic
changes, including aberrant DNA methylation, histone modifica-
tions, and nucleosome positioning, although this remains to
be demonstrated. These epigenetic alterations can lead to
abnormal gene expression and genomic instability, which may
predispose to cancer (Rodrı´guez-Paredes and Esteller, 2011;
Wilson and Roberts, 2011).
Figure 1. The Crosstalk between Cancer Genetics and Epigenetics
Themethylation of CpG sites located inDNMT3A exons (epigenetic alteration, represented as a black circle) potentially leads to genetic mutation in somatic cells
by the hydrolytic deamination of 5mC to form a C to T transition mutation. Although it is not known whether DNMT3A directly methylates its own exon and the
effect of this genetic mutation is not yet fully understood, it is possible that the C to T transition alters DNMT3A function and/or activity and thereby disrupts the
epigenetic landscape. The Yin-Yang diagram emphasizes how epigenetic and genetic interactions are required to achieve perfect balance and suggests that
disruption of the balance can lead to disease.
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While non-CpG methylation has been reported in pluripotent
cells (Hawkins et al., 2010; Meissner et al., 2008), DNA methyla-
tion in mammals occurs predominantly at CpG dinucleotides,
and methylation of CpG islands acts as a relatively stable gene
silencing mechanism (Jones and Liang, 2009). The majority of
the CpG islands, which represent over 50% of promoters,
remain mostly unmethylated in somatic cells. DNA methylation
is important for the regulation of non-CpG island as well as
CpG island promoters and in repetitive sequences (LINE and/
or SINE) to maintain genomic stability (De Carvalho et al.,
2010; Jones and Liang, 2009). DNA methylation in mammalian
cells is regulated by a family of DNAmethyltransferases (DNMTs)
that catalyze the transfer of methyl groups from S-adenosyl-L-
methionine to the 50 position of cytosine bases in the CpG
dinucleotide. DNMT3A and DNMT3B, which are expressed
throughout the cell cycle (Kinney and Pradhan, 2011), establish
new DNA methylation patterns early in development. During
replication, the original DNA methylation pattern is maintained
largely by DNMT1 activity, which prefers hemi-methylated DNA
over nonmethylated DNA as a substrate and which is also sup-
ported by recent structure study (Song et al., 2012) and is there-
fore responsible for the maintenance of methylation patterns
during cell division, with some participation by DNMT3A and
DNMT3B (Jones and Liang, 2009; Sharma et al., 2010).DNMT1 mutations have been described in colorectal cancer
(Kanai et al., 2003), and as previously noted, DNMT3Amutations
are frequent in myelodysplastic syndromes (MDS) and AML (Ley
et al., 2010; Yamashita et al., 2010; Yan et al., 2011). Germline
mutations in DNMT3B underlie immunodeficiency-centromeric
instability-facial anomalies (ICF) syndrome and chromosome
instability (Wijmenga et al., 2000), and SNPs in DNMT3B have
been suggested to be associated with risk of several cancers
including breast and lung adenocarcinoma (Shen et al., 2002).
In addition to the example in Figure 1, other mutations of
DNMT3A occur at several positions and generally represent
a loss of function, similar to DNMT3Bmutations that are associ-
ated with ICF syndrome (Ley et al., 2010). Recent studies
uncovered a role of DNMT3A in silencing self-renewal genes in
hematopoietic stem cells (HSCs) to permit efficient hematopoi-
etic differentiation, and its loss progressively impairs HSC differ-
entiation (Challen et al., 2012; Trowbridge and Orkin, 2012). All
known DNMT3A mutations are related to poor survival in AML
(Ley et al., 2010; Yan et al., 2011), suggesting that these muta-
tions prevent differentiation and have an important role in the
progression of disease.
In addition to various mutations, DNMT1, DNMT3A, and
DNMT3B are often overexpressed in various cancers and
possibly contribute to ectopic hypermethylation (Wu et al.,
2007). However, careful studies should be done to understandCancer Cell 22, July 10, 2012 ª2012 Elsevier Inc. 11
Table 1. Epigenetic Modifiers in Cancer
Gene Function Tumor Type Alteration
DNA
methylation
DNMT1 DNA methyltransferase Colorectal, non-small cell lung,
pancreatic, gastric, breast cancer
Mutation (Kanai et al., 2003)
Overexpression (Wu et al., 2007)
DNMT3A DNA methyltransferase MDS, AML Mutation (Ley et al., 2010;
Yamashita et al., 2010;
Yan et al., 2011)
DNMT3B DNA methyltransferase ICF syndrome, SNPs in breast
and lung adenoma
Mutation (Wijmenga et al., 2000)
Mutation (Shen et al., 2002)
MBD1/2 Methyl binding protein Lung and breast cancer Mutation (Sansom et al., 2007)
TET1 50methylcytosine hydroxylase AML Chromosome translocation
(De Carvalho et al., 2010;
Wu and Zhang, 2010)
TET2 50methylcytosine hydroxylase MDS, myeloid malignancies
(AML), gliomas
Mutation/silencing
(Tan and Manley, 2009)
IDH1/2 Isocitrate dehydrogenase Glioma, AML Mutation (Figueroa et al., 2010;
Lu et al., 2012; Turcan et al., 2012)
AID 50cytidine deaminase CML Aberrant expression





Bladder TCC, ALL and AML,
non-Hodgkin lymphoma,
B cell lymphoma, prostate
(primary)
Translocation, mutation, aberrant
expression (Gui et al., 2011;
Morin et al., 2011)





(Filippakopoulos et al., 2010;









(Chase and Cross, 2011;
Tsang and Cheng, 2011)
ASXL Enhancer of trithorax and
polycomb group (EAP)
Additional sex combs like 1
MDS and AML, Bohring-Opitz
syndrome
Mutation (Gelsi-Boyer et al., 2012;
Hoischen et al., 2011)
BMI-1 PRC1 subunit Ovarian, mantle cell lymphomas
and Merkel cell carcinomas
Overexpression (Jiang et al., 2009;
Lukacs et al., 2010)
G9a Histone methyltransferase
H3K9
HCC, cervical, uterine, ovarian,
and breast cancer
Aberrant expression




(Miremadi et al., 2007)
LSD1 Histone demethylase
H3K4/H3K9
Prostate Mutation (Rotili and Mai, 2011)
UTX (KDM6A) Histone demethylase H3K27 Bladder, breast, kidney, lung,
pancreas, esophagus, colon,
uterus, brain
Mutation (Rotili and Mai, 2011)
JARID1B/C Histone demethylase
H3K4/H3K9
Testicular and breast, RCCC Overexpression
(Rotili and Mai, 2011)
EP300 Histone deacetyltransferase Breast, colorectal, pancreatic
cancer
Mutation (Miremadi et al., 2007)
CREBBP Histone acetyltransferase Gastric and colorectal, epithelial,
ovarian, lung, esophageal cancer
Mutation, overexpression
(Miremadi et al., 2007)
PCAF Histone acetyltransferase Epithelial Mutation (Miremadi et al., 2007)
HDAC2 Histone deacetyltransferase Colonic, gastric, endometrial
cancer
Mutation (Ropero et al., 2006)
SIRT1,
HDAC5/7A
Histone deacetyltransferase Breast, colorectal, prostate
cancer
Mutation, aberrant expression
(Miremadi et al., 2007)



















BRG1 (SMARCA4) ATPase of BAF Lung, rhabdoid, medulloblastoma Mutation, low expression
(Wilson and Roberts, 2011)
BRM (SMARCA2) ATPase of BAF Prostate, basal cell carcinoma Mutation, low expression
(de Zwaan and Haass, 2010;
Sun et al., 2007)
ARID1A (BAF250A) BAF subunit Ovarian clear cell carcinomas,
30% of endometrioid carcinomas,
endometrial carcinomas
Mutation, genomic rearrangement,
low expression (Guan et al., 2011;
Jones et al., 2010)
ARID2 (BAF200) PBAF subunit Primary pancreatic
adenocarcinomas
Mutation (Li et al., 2011)
BRD7 PBAF subunit Bladder TCC Mutation (Drost et al., 2010)
PBRM1 (BAF180) PBAF subunit Breast tumors Mutation (Varela et al., 2011)
SRCAP ATPase of SWR1 Prostate Aberrant expression
(Balakrishnan et al., 2007)





(Mattera et al., 2009)
CHD4/5 ATPase of NURD Colorectal and gastric cancer,
ovarian, prostate, neuroblastoma
Mutation (Bagchi et al., 2007;
Kim et al., 2011; Wang et al., 2011a)
CHD7 ATP-dependent helicase Gastric and colorectal Mutation (Wessels et al., 2010)
MDS, myelodysplastic syndromes; AML, acute myeloid leukemia; TCC, transitional cell carcinoma; RCCC, renal clear cell carcinoma.
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ation disruption since the overexpression of DNMTs may be
a reflection of increased cell proliferation.
Methyl-binding domain (MBD) proteins, including MeCP2,
MBD1, MBD2, and MBD4, bind to methylated CpG sites and
might be involved in mediating transcriptional repression
(Bogdanovic and Veenstra, 2009). Genetic mutations in MBD1
and MBD2 increase the risk of lung and breast cancer, respec-
tively (Sansom et al., 2007). MeCP2 and other MBD protein alter-
ations have been reported in several cancers, however the
mechanism is yet to be uncovered.
The field of DNA demethylation has been controversial (Ooi
and Bestor, 2008), but recent evidence suggests that this deme-
thylation can occur through two processes: active and passive
(De Carvalho et al., 2010; Wu and Zhang, 2010). Passive DNA
demethylation occurs when maintenance DNA methylation is
impaired during DNA replication, resulting in loss of methylation
of the newly synthesized DNA strand. In contrast, active DNA
demethylation is dependent on the ability of one or more
enzymes to hydroxylate, further oxidize, or deaminate 5mC
and can occur independent of DNA replication (Bhutani et al.,
2011; Wu and Zhang, 2010). Recently, several proteins have
been implicated to be erasers of DNA methylation including
TET (ten-eleven-translocation) and AID (activation-induced
cytidine deaminase) (De Carvalho et al., 2010; Ko et al., 2010;
Wu and Zhang, 2010). Active DNA demethylation is currently
thought of as being a stepwise process—hydroxylation of 5mC(5hmC) by TET proteins followed by deamination by AID/
APOBEC protein or carboxylation and entry in to the subsequent
base excision repair pathway (Bhutani et al., 2011). Alternatively,
5hmC is not recognized by DNMT1 (Lao et al., 2010); replication
of DNA containing this base would lead to loss of the 5mC mark
in the subsequent S phase.
Three TET family members (TET1, TET2, and TET3) have been
reported so far, and each protein seems to have a distinct
function in different cellular contexts (Cimmino et al., 2011).
Mutations in TET2, including frame shift, nonsense, and
missense mutations, have been found in MDS and in myelopro-
liferative neoplasms (Tan andManley, 2009). Notably, TET2 loss-
of-function mutations were mutually exclusive of mutations in
IDH1 (isocitrate dehydrogenase1) and IDH2, which are known
to induce DNA hypermethylation and impair differentiation in
hematopoietic cells (Figueroa et al., 2010). IDH1/2 mutations in
glioma and AML cause accumulation of 2-hydoxyglutarate
which is called an ‘‘oncometabolite’’ and further impairs the
DNA demethylation process and causes hypermethylation in
glioma (Turcan et al., 2012). Remarkably, IDH1/2 mutations
also disrupt histone demethylation and block cell differentiation
in nontransformed cells (Lu et al., 2012).
Considering that DNMTs/MBD proteins and enzymes involved
in DNA demethylation contribute directly to the level of DNA
methylation but also to nucleosome occupancy patterns, the
alteration of these machineries in cancer development could
be broader than previously realized.Cancer Cell 22, July 10, 2012 ª2012 Elsevier Inc. 13
Figure 2. Genetic Mutations in Epigenetic Modifiers in Cancer
The drawing shows the interaction between epigenetic processes in speci-
fying gene expression patterns. Recent whole exome sequencing studies
show that mutations in the three classes of epigenetic modifiers is frequently
observed in various types of cancers, further highlighting the crosstalk
between genetics and epigenetics. Examples of some but not all of these
mutations that are discussed in this review are shown. The mutations of
epigenetic modifiers probably cause genome-wide epigenetic alterations in
cancer, but these have yet to be demonstrated in a genome-wide scale.
Understanding the relationship of genetic and the epigenetic changes in
cancer will offer novel insights for cancer therapies.
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Nucleosomes, which are the basic building blocks of chromatin,
contain DNA wrapped around histones (Luger et al., 1997).
Histones are regulators of chromatin dynamics either by
changing chromatic structure by altering electrostatic charge
or providing protein recognition sites by specific modifications
(Mills, 2010; Suganuma and Workman, 2011). Histone modifica-
tions at specific residues characterize genomic regulatory
regions, such as active promoter regions which are enriched
in trimethylated H3 at lysine 4 (H3K4me3), inactive promoters
which are enriched in trimethylated H3 at lysine 27 (H3K27me3)
or trimethylated H3 at lysine 9 (H3K9me3), and regulatory
enhancers that are enriched in monomethylated H3 at lysine 4
(H3K4me1) and/or acetylatedH3at lysine27 (H3K27ac) (Hawkins
et al., 2011; Hon et al., 2009; Mills, 2010). These histone modif-
ication patterns are regulated by enzymes including histone
acetyltransferases (HATs) and deacetylases (HDACs), which
introduce and remove acetyl groups, respectively. Histonemeth-
yltransferases (HMTs) and demethylases (HDMs), on the other
hand, introduce and remove methyl groups. During tumorigen-
esis, cells undergo global changes in histone modifications and
in the distribution of histone variants such as H2A.Z (Conerly
et al., 2010), which may affect the recruitment of TFs and often
components of the transcriptionmachinery, thereby contributing
to aberrant gene expression (Mills, 2010; Sharma et al., 2010).
The acetylation of lysine residues on histones is generally
associated with active gene transcription. HATs can be grouped
into three categories based on their sequence similarities: Gcn5/
PCAF, p300/CBP, and the MYST families (Yang, 2004). Muta-
tions or translocations of these genes are observed in colon,14 Cancer Cell 22, July 10, 2012 ª2012 Elsevier Inc.uterine, and lung tumors and in leukemias (Esteller, 2007).
Further, these HATs (p300, CBP, and MYST4) are commonly
involved in chromosomal translocations in hematological
cancers rather than in solid tumors (Iyer et al., 2004). For
example, AML1-ETO, the fusion protein generated by the
t(8;21) translocation, which is also the most common fusion
protein in AML, requires its acetylation mediated by p300 for
oncogenic activity (Wang et al., 2011b). HDACs remove acetyl
groups from histone tails, and at least 18 HDAC genes have
been identified in the human genome. HDACs as well as
HATs function as part of large multi-protein complexes (Marks
et al., 2001). HDACs have been implicated in cancer due to
their aberrant binding and consequent silencing of tumor sup-
pressor genes. For example, hypoacetylation of the p21waf1/
cif1 (CDKN1A) promoter results in its silencing and can be
reversed by HDAC inhibitors (Ocker and Schneider-Stock,
2007). Germline mutations of HDACs increase the risk of breast
and lung cancers, and abnormal HDAC overexpression has also
been observed in various cancers (Miremadi et al., 2007). As
a result, HDAC inhibitors have been developed as anti-cancer
drugs (Shankar and Srivastava, 2008). Several independent
reports have identified truncation mutations in HDAC2 in epithe-
lial, colonic, gastric, and endometrial cancers, and these muta-
tions confer resistance to HDAC inhibitors (Smith and Workman,
2009). Screening for thesemutationsmay improve the efficacy of
HDAC inhibitors. Conversely, there is evidence that HDACs may
function as tumor suppressors by maintaining proper chromatin
structure and further stabilizing the genome (Bhaskara et al.,
2010). Potentially, either loss or gain of function mutations of
HDACs could contribute to tumorigenesis.
In addition to chromatin modifying enzymes, chromatin
binding proteins or so-called epigenetic ‘‘readers’’, such as the
bromodomain proteins which read lysine acetylation marks,
can also play an important during tumorigenesis. For example,
the fusion of the bromodomain protein Brd4 with nuclear protein
in testis (NUT) results in the development of aggressive NUT
midline carcinoma (Filippakopoulos et al., 2010). Aberrant regu-
lation of Brd4 has also been reported in other cancers such as
colon and breast, suggesting that the selective inhibitors which
target these kinds of epigenetic readers may give us a novel
clue for cancer therapy (Filippakopoulos et al., 2010; Zuber
et al., 2011).
Methylation of arginine and lysine residues on histones or
nonhistone proteins such as TFs regulate chromatin structure
and therefore gene expression (Greer and Shi, 2012). The best-
known example of alterations in HMTs during tumorigenesis
may be in the mixed lineage leukemia (MLL) protein, which intro-
duces the active H3K4me3 mark and plays important roles in
development. MLL is located on chromosome 11q23, which is
a common region of chromosomal translocation in AML and
ALL (Slany, 2009). Translocations of MLL with multiple different
partners can result in the generation of fusion proteins that are
frequently associated with tumorigenesis and poor prognosis
by generating abnormal patterns of H3K4me3 and/or recruiting
other epigenetic modifiers (Balgobind et al., 2011). These MLL
fusion proteins have close relationships with other epigenetic
modifiers and cause altered epigenetic programs in cancer.
For example, the aberrant H3K79 methylation pattern mediated
by DOT1L is required for the maintenance of the MLL
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Inhibition of DOT1L activities decreases expression of MLL
fusion-driven transcriptional programs and might have profound
therapeutic implications (see the detailed discussion in Thera-
peutic Perspective). In addition, alternative splicing and muta-
tions in MLL1, MLL2, and MLL3 genes have been identified in
bladder, breast, and pancreatic cancers and in glioblastoma
(Gui et al., 2011; Morin et al., 2011).
The Polycomb group (PcG) of repressor proteins controls the
accessibility of gene regulatory elements to the transcription
machinery (Mills, 2010), This group is crucial for early develop-
ment and often becomes deregulated in cancer. EZH2, together
with SUZ12 and EED, form the polycomb repressive complex 2,
which methylates H3K27. Overexpression of EZH2 has been
reported in several cancers such as prostate, breast, lung,
and bladder and seems to result in an increase in H3K27me3
(Chase and Cross, 2011). However, other studies show that
there is no association between EZH2 and H3K27me3 in ovarian
and pancreatic cancers (Fu¨llgrabe et al., 2011). Downregulation
of microRNA-101, a negative regulator of EZH2, has been
described as a cause of overexpression of EZH2 in bladder
and prostate cancers (Friedman et al., 2009; Varambally et al.,
2008), and EZH2 mutations have been reported in lymphoma
and myeloid neoplasm (Chase and Cross, 2011). In lymphoma,
a heterozygous missense mutation at amino acid Y641, within
the SET domain, results in a gain of function, showing enhanced
catalytic activity. The EZH2mutations in myeloid neoplasms are
associated with poor prognosis, and the mutations frequently
result in loss of function of HMT. Although the mechanism of
action of EZH2 in cancer is not yet clear, it appears to play
a role in growth control (Tsang and Cheng, 2011).
BMI-1, a component of PRC1, is indispensable for the regula-
tion of self-renewal of normal and leukemic stem cells and for
the differentiation of T cells (Nakayama and Yamashita, 2009;
Sauvageau and Sauvageau, 2010). BMI-1 has been considered
a key regulator of self-renewal in cancer stem cells (Jiang
et al., 2009). More recently, overexpression of BMI-1 has been
observed in solid tumors such as prostate cancer (Lukacs
et al., 2010; Yang et al., 2010).
Subgroups of genes that are normally repressed by
H3K27me3 in early development often acquire abnormal DNA
methylation in cancers, a process which we have called
‘‘epigenetic switching’’ (Sharma et al., 2010). The differentiation
of stem cells begins by turning off master regulators that define
‘‘stemness’’ (e.g., OCT4 in embryonic stem cells), followed by
the expression of lineage specific genes, resulting in the acquisi-
tion of particular phenotypes (e.g., MYOD1 in muscle and
NEUROG1 in neurons) (Young, 2011). Progress through these
steps is often, but not always, controlled by PcG and does not
involve DNA methylation. Once these key regulators become
methylated, they become locked in a repressed state, and this
prevents switching from one phenotype to another. The outcome
of the ‘‘epigenetic switch’’ may therefore be an increase in the
number of cancer initiating cells (Baylin and Jones, 2011). Full
understanding of this mechanism remains to be clarified.
Other lysine HMTs (NSD1, SMYD3, and G9a) are aberrantly
expressed in several cancers (Varier and Timmers, 2011).
Evidence for the role of arginine HMTs (PRMTs) in tumorigenesis
has not been aswell established as that of lysine HMTs, althoughalteration of expression of PRMT1 in breast cancer and PRMT5
in gastric cancer has been reported (Lee and Stallcup, 2009).
Two distinct classes of HDMs have been defined based on
their mechanism of action (Mosammaparast and Shi, 2010).
Lysine-specific histone demethylase 1 (LSD1), lysine-specific
demethylase 6A (KDM6A/UTX), and jumonji C-domain contain-
ing proteins (JARID1A-D) have all been implicated in tumorigen-
sis. Mutations in LSD1 (prostate cancer) and KDM6A/UTX
(various cancers including bladder, breast, kidney, and colon)
have been reported (Rotili and Mai, 2011). Reintroduction of
KDM6A/UTX in the UTX mutant cancer cells results in the slow-
ing of proliferation, suggesting that genetic mutations of these
enzymes reinforce the epigenetic deregulation in cancers.
The exact mechanism by which these histone modifying
enzymes affect tumorigenesis remains to be elucidated; altered
expression of histone modifiers caused by mutations may
disrupt whole epigenetic regulation mechanisms and result in
aberrant gene expression patterns. Indeed, the disruption of
histone modifications has been linked to all the hallmarks of
cancer, and it is important to be aware that a precise balance
between the enzymes that write, read, and erase histone marks
is crucial in preventing tumorigenesis.
Chromatin Remodeling Complexes
Nucleosome occupancy is a key mechanism for gene expres-
sion, and it has been known for some time that chromatin remod-
elers are responsible for regulating this process (Clapier and
Cairns, 2009; Segal and Widom, 2009; Valouev et al., 2011).
ATP dependent chromatin remodelers are generally divided
into four main families: switch/sucrose non-fermenting (SWI/
SNF), imitation SWI, inositol requiring 80, and nucleosome
remodeling and deacetylation chromatin helicase DNA binding
(NURD/Mi2/CHD) complexes (Ho and Crabtree, 2010). Although
the ATPase domains are highly similar, the distinct chromatin in-
teracting domains carry out specific roles and can be selectively
targeted. These ATPase dependent remodelers act in the
context of multisubunit complexes and have dual roles as activa-
tors and repressors of gene expression. The importance of
chromatin remodeling machines is becoming apparent with the
realization that many of them are mutated in several types of
cancer (Hargreaves and Crabtree, 2011; Wilson and Roberts,
2011).
SWI/SNF is a large complex with 9 to 12 subunits including
ATPases (BRG1 or BRM), core subunits (SNF5, BAF155, and
BAF 170), and other accessory subunits (Ho and Crabtree,
2010). The variety of subunits allows for combinatorial assembly
that leads to functional diversity as evidenced by the cellular
stage-specific composition of SWI/SNF complexes (Hargreaves
and Crabtree, 2011). SWI/SNF complexes remodel chromatin by
changing nucleosome occupancy pattern, thereby contributing
to either transcriptional activation or repression (Reisman et al.,
2009; Wilson and Roberts, 2011).
SNF5 of the SWI/SNF core subunit is at the nexus of the link
between chromatin remodeling and tumorigenesis, and many
rhabdoid tumors contain inactivating mutations in this gene.
Loss of SNF5 is also observed in renal carcinomas and mela-
nomas, where it is correlated with poor survival rates (Lin et al.,
2009). SNF5 loss affects expression of genes associated
with cell proliferation and cell cycle, such as RB or p53 and
Hedgehog-Gli, a key signaling pathway in early developmentCancer Cell 22, July 10, 2012 ª2012 Elsevier Inc. 15
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reported during tumorigenesis (Jagani et al., 2010; Wilson and
Roberts, 2011), and there is accumulating evident that SNF5
deletion plays a role in tumorigenesis, but the exact mechanism
of SNF5 loss in tumorigenesis remains to be elucidated.
ARID1A/BAF250amutations have been frequently observed in
ovarian clear cell carcinoma (50%) and endometrioid carci-
nomas (30%) (Guan et al., 2011; Jones et al., 2010; Wiegand
et al., 2010). More recently, ARID1A/BAF250a mutations have
been observed in primary pancreatic adenocarcinomas, and
transitional cell carcinoma and low ARID1A expression was
found to be significantly associated with a specific subgroup
of breast cancers (ER-/PR-/HER2-) (Zhang et al., 2011). In
mice, ARID1B/ BAF250b-containing complexes, which include
components of an E3 ubiquitin ligase and are mutually exclusive
of ARID1A, have also been shown to play a role in the control of
cell cycle and differentiation. Mutations in human ARID1B/
BAF250b have been reported very recently as a cause of
Coffin-Siris syndrome (Santen et al., 2012; Tsurusaki et al., 2012).
The PBRM1/BAF180, BAF200, and BRD7 subunits belong
to polybromo BRG1 associated factor (PBAF) complexes and
facilitate transcriptional activation by nuclear receptors (Wilson
and Roberts, 2011). Mutation of PBRM/BAF180 has been iden-
tified in 41% renal cell carcinomas and in breast cancers, and
this mutation affects senescence in human cells. Mutation in
another PBAF specific subunit, BRD7, has been reported in
breast cancers. Since BRD7 has a variety of binding partners
including p53 and BRCA1, mutations in it may be important in
tumorigenesis.
Mutations in SWI/SNF ATPase subunits BRG1 or BRM have
been reported in several cancers including lung, medulloblas-
toma, rhabdoid, and prostate tumors (Wilson and Roberts,
2011). Although BRG1 and BRM show some redundancy in vivo
and in vitro, they seem to bemutually exclusive and have distinc-
tive roles based on their expression changes during early devel-
opment. Tumor suppressor properties of BRG1 and BRM have
been reported in lung, breast, and prostate cancer cell lines
(Roberts and Orkin, 2004) and, in vitro, BRG1 and BRM have
been observed to interact with several tumor suppressors
including BRCA1(Wang et al., 2007).
Mutation of BAF complexes is a frequent event in various
cancers; however, the dependency between the subunits and
whether mutation of one subunit results in a modification of the
activity of the complex is not clear. In addition, mutations of
BAF complex components frequently coexist with those of
canonical oncogenes or tumor suppressors such as KRAS,
CDKN2A, or p53, suggesting a synergistic effect on tumorigen-
esis (Wilson and Roberts, 2011).
In addition to SWI/SNF complexes, mutations of other ATP
dependent chromatin remodelers are beginning to be identified
in several cancers (Clapier and Cairns, 2009; Hargreaves and
Crabtree, 2011; Ho and Crabtree, 2010). Despite emerging
evidence that closely connects these ATPase remodelers in
tumorigenesis, the direct causality and/or mechanism still
remains to be explicated.
The Role of SNPs on Epigenetic Regulation and Cancer
Genome-wide association studies have identified a large
number of SNPs associated with an increased risk of a variety16 Cancer Cell 22, July 10, 2012 ª2012 Elsevier Inc.of diseases including several cancers. Surprisingly, cancer-
associated SNPs are significantly enriched at regions defined
as functional enhancers in ES cells (Teng et al., 2011) and might
confer cancer susceptibility by altering the chromatin landscape.
Further, several genome-wide expression quantitative trait loci
studies in humans have demonstrated a link between genetic
variation and changes in gene regulation (Nica et al., 2010;
Nicolae et al., 2010). More recently, these genetic variants
were shown to modify the chromatin accessibility of TF binding
sites, thereby leading to gene expression differences (Degner
et al., 2012). Although allele-specific DNA methylation and
allele-specific gene expression have been well studied in
imprinting and X chromosome inactivation, recent studies
show that these allele-specific phenomena are more pervasive
to other cellular activities (Tycko, 2010). Notably, most of the
allele-specific DNA methylation outside of imprinted genes
shows a strong correlation with SNP genotypes that affect TF
binding insulators and long-range chromosome structure.
Conversely, SNPs can create or delete CpGs (termed as CpG
SNPs), thereby influencing the binding of specific TFs (Tycko,
2010). Future studies aimed at understanding functional associ-
ations among epigenetic variation (epigenotype), genetic varia-
tion (genotype), and trait or disease (phenotype) may help us to
determine the causality of diseases.
Therapeutic Perspective
An increasing number of nucleoside analogs/small molecules
are being studied as anti-cancer drugs. Inhibitiors of DNMTs
5-azacytidine (5-Aza-CR; Vidaza; azacitidine) and 5-Aza-2-
deoxycytidine (5-Aza-CdR; Dacogen; decitabine) or HDACs by
SAHA or Rhomidepsin have been approved for cancer treatment
by the FDA and proven to have therapeutic efficacy in a variety
of malignancies (Kelly et al., 2010). Recently, several novel
compounds have been reported to target epigenetic compo-
nents and have therapeutic effects in the presence of specific
genetic defects. The DOT1L inhibitor (EPZ004777) inhibits
H3K79 methylation, prevents transcription of genes that are
involved in leukemogenesis, and kills cancer cells bearing MLL
translocations (Daigle et al., 2011). Selective bromodomain
inhibitors (JQ1 or GSK525762) (Filippakopoulos et al., 2010;
Nicodeme et al., 2010) inhibit transcription by MYC, which is
overexpressed in a majority of cancers (Delmore et al., 2011).
The presence of multiple genetic and epigenetic aberrations
within a cancer suggests that effective cancer therapies will be
most beneficial when combined with epigenetic and/or other
anti-cancer strategies such as standard chemotherapy (Juer-
gens et al., 2011; Matei and Nephew, 2010).
Conclusions
Recent whole exome sequencing of thousands of human
cancers have come up with the unexpected results that muta-
tions in genes that control the epigenome are surprisingly
common in human cancers. The presence of these mutations
was unknown and overlooked, which is surprising in view of
the fact that were almost 1,000 cell lines recently analyzed by
whole exome sequencing contain a large number of potential
mutations in epigenetic modifiers (Barretina et al., 2012). The
fact that the epigenome acts at the pinnacle of the hierarchy of
gene control mechanisms means that the mutations probably
Cancer Cell
Reviewhave effects on multiple pathways relevant to the cancer pheno-
type, and a single mutation could cause wide scale misregula-
tion. This realization opens the door to further drug development
since it might be possible to correct several pathways by altering
or inhibiting one enzyme. These data also show a much closer
Yin-Yang relationship between the genome and the epigenome,
as indicated in this review. This has heralded the dawn of a new
era in cancer research in which the way the genes are organized
and controlled is being recognized as a major relevant factor for
human carcinogenesis. Traditionally, cancer is diagnosed by
pathologists using light microscopes to analyze the morphology
of the nucleus among other cellular features. Understanding how
epigenetic modifiers communicate with each other and alter
nuclear architecture, and therefore gene expression, is a major
challenge for the future but one which should yield better options
for patients.
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